Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
OBJECTIVE
To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI).


METHODS
In a prospective observational study, monthly intravenous pamidronate infusions were given to 43 children (aged 4 months-16 years) with different severity and form of OI. Outcome measures included the Pediatric Evaluation of Disability Inventory (PEDI), a score of well-being, registration of days with pain and bone density measured by using dual energy X-ray absorptiometry (DXA). Data were collected before and after the first year of treatment.


RESULTS
Self-care and mobility measured by PEDI increased significantly in both the Functional Skill scale and in the Caregiver Assistance scale. The youngest children improved more than the older ones according to the PEDI. The days with skeletal pain were reduced and both well-being and bone density increased.


CONCLUSIONS
Intravenous treatment with bisphosphonates influenced health status, according to the International Classification of Functioning, Disability and Health (ICF). This group of 43 children experienced beneficial effects on everyday activities, skeletal pain, well-being and bone density.
Löwing
Kristina
K
Department of Woman and Child Health, Astrid Lindgren Children's Hospital, Karolinska Institutet, Sweden. kristina.lowing@ki.se
Aström
Eva
E
Oscarsson
Katarina Allbrink
KA
Söderhäll
Stefan
S
Eliasson
Ann-Christin
AC
D015502:Absorptiometry, Photon; D000293:Adolescent; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008134:Long-Term Care; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy*; D010146:Pain / Q000517:prevention & control; D000077268:Pamidronate; D011446:Prospective Studies; D012107:Research Design; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate